Boehringer Bigs Up US and China As Europe Sales Slip
Executive Summary
Away from the pricing pressures, reimbursement battles and problems of patent expiries in its home continent, the German major is counting on the US and China to provide the best opportunities for future growth.
You may also be interested in...
Jardiance Is The Star Of Boehringer’s Show, But Micardis Drag Spoils The Party
Jardiance growth offsets Micardis woes as the German major updates the industry on its H1.
Tech Transfer Roundup: Vanderbilt Teams With Deerfield; Expands Cancer Pact With Boehringer
Vanderbilt launches new biotech with Deerfield aimed at reworking the drug development paradigm, while also expanding its cancer research work with BI. Grunenthal partners with Katholieke Universiteit Leuven to investigate ion channel modulation approaches in pain.
With Dicerna's NASH Asset, Boehringer Found What It Was Looking For
In eyeing NASH, the firms both zeroed in on the same target, considered inaccessible to traditional modalities. The deal gives BI an RNAi approach, joining its Phase II anti-inflammatory candidate for NASH.